Non-small cell lung cancer
Conditions
Interventions
afatinib
Sponsors
Hirosaki University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Histologically or cytologically proven non-small cell lung cancer 2)Harboring sensitive EGFR mutation 3)More taan 3 weeks from prior chomotherapy 4)More than 12 weeks from the RT therapy 5)More than 2 weeks from pleurodesis 6)Performance status: 0-1 7)More than 75 years old 8)Adequate organ functions 9)PaO2 >= 60torr or SpO2 >= 95% at room air 10)Life expectancy: over 3 months 11)Written informed consent
Exclusion criteria
Exclusion criteria: 1)Having severe complications 2)Symptomatic brain metastases 3)Interstitial pneumonitis on chest Xray 4)Past history of severe allergic reactions to drugs 5)Pregnant or breastfeeding woman 6)Receiving steroids or immunosuppressants 7)Active infectious disease 8)Uncontrollable pleural effusion or pericardial effusion 9)Active double cancer 10)Patients whose physicians considered as inappropriate for this clinical study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To conclude maximum tolerated dose and recommended phase II dose. | — |
Countries
Japan
Contacts
Public ContactHisashi Tanaka
Hirosaki University Graduate School of Medicine Cardiology, Respiratory medicine and Nephrology
Outcome results
None listed